Atrial fibrillation (AF) is a major source of cardiovascular disease morbidity and mortality and an important public health problem. It is estimated that the prevalence of AF in the U.S. alone will rise from 2.3 million in 2001 to more than 6 million in 2050. Although our understanding of the prevalence and clinical consequences of AF is sound, important gaps remain. First, clinical guidelines for the management of AF exist, but the extent to which the care of patients with AF in community settings is consistent with these guidelines and is unclear. In addition, how care varies by age, sex, race, geography (e.g., region, urban vs. rural location) and over time is understudied. Second, a number of new technologies have been associated with altered morbidity and mortality in randomized clinical trials, but the extent to which those technologies are used in routine clinical practice is unknown. Finally, we have little empirical evidence about how the resources expended to treat AF translate into improved outcomes. The objective of the proposed project, Patterns of Healthcare Use, Treatment &Outcomes of Atrial Fibrillation: PATH-AF, is to improve our understanding of the aforementioned issues. Our efforts are organized under three Specific Aims:
Aim 1 will document the extent to which clinical practice reflects established guidelines and will examine how guidelines-based care and standard care for AF varies by age, sex, race, geography and over time.
Aim 2 will analyze the use of emerging technologies to monitor and treat AF patients, including the use of home monitoring devices to measure INR and the use of radiofrequency catheter ablation. Again, in subgroup analyses we will examine differential use by age, sex, race, and geography.
Aim 3 will examine the relations between health care use, outcomes and costs in patients with AF. In summary, AF is a major contributor to morbidity and mortality in the population. We bring together a multi- institutional, multidisciplinary team with expertise in AF, health services research, epidemiology, primary care, heart failure, and statistics. We propose to leverage existing cohorts and registries linked with claims to provide a comprehensive picture of healthcare use, treatment, and outcomes of AF in the U.S. The findings will advance our understanding of the treatment of AF in "real-world" settings and build the capacity to use cohort-claims linked data sets to inform current discussions about value in health care.

Public Health Relevance

The proposed research is relevant to the public health in two ways. First, it will provide a comprehensive understanding of the health care of patients with atrial fibrillation in the United States. Second, it will directly answer critical questions of how investments in health care for patients with atrial fibrillation are directly linked to survival and health.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL102214-03
Application #
8286308
Study Section
Health Services Organization and Delivery Study Section (HSOD)
Program Officer
Boineau, Robin
Project Start
2010-05-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2014-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$438,684
Indirect Cost
$80,114
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Kwon, Younghoon; Norby, Faye L; Jensen, Paul N et al. (2016) Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). PLoS One 11:e0147065
Magnani, Jared W; Wang, Na; Benjamin, Emelia J et al. (2016) Atrial Fibrillation and Declining Physical Performance in Older Adults: The Health, Aging, and Body Composition Study. Circ Arrhythm Electrophysiol 9:e003525
Rahman, Faisal; Wang, Na; Yin, Xiaoyan et al. (2016) Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm 13:233-40
Rahman, Faisal; Ko, Darae; Benjamin, Emelia J (2016) Association of Atrial Fibrillation and Cancer. JAMA Cardiol 1:384-6
Ko, Darae; Riles, Eric M; Marcos, Ernaldo G et al. (2016) Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study). Am J Cardiol 118:1493-1496
Wallace, Erin R; Siscovick, David S; Sitlani, Colleen M et al. (2016) Incident Atrial Fibrillation and Disability-Free Survival in the Cardiovascular Health Study. J Am Geriatr Soc 64:838-43
Lee, Jane J; Yin, Xiaoyan; Hoffmann, Udo et al. (2016) Relation of Pericardial Fat, Intrathoracic Fat, and Abdominal Visceral Fat With Incident Atrial Fibrillation (from the Framingham Heart Study). Am J Cardiol 118:1486-1492
Kim, Eun-Jeong; Yin, Xiaoyan; Fontes, João D et al. (2016) Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study). Am Heart J 177:138-44
Roberts, Jason D; Dewland, Thomas A; Glidden, David V et al. (2016) Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J 175:9-17
Steinberg, Benjamin A; Greiner, Melissa A; Hammill, Bradley G et al. (2015) Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther 33:177-83

Showing the most recent 10 out of 74 publications